Allergan plc (AGN)
(Delayed Data from NYSE)
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$145.81 USD
+1.56 (1.08%)
Updated May 3, 2019 04:01 PM ET
After-Market: $145.88 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study
by Zacks Equity Research
Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.
The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Abbott Labs, Allergan, Johnson & Johnson and Merck
3 Dividend-Paying Large Cap Pharma Stocks to Consider for 2020
by Christopher Vargas
The stock market continued its end of the year rally Friday as the three major indices all hit new intraday highs.
Bull of the Day: InMode (INMD)
by Tracey Ryniec
What will you do to look good on Instagram?
Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy
by Zacks Equity Research
Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Allergan (AGN) Up 4.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca Sells Schizophrenia Drug Rights in US and Canada
by Zacks Equity Research
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
NASH Scorecard Year to Date: The Winners and the Losers
by Ekta Bagri
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
3 Stocks for Value Investors to Buy as Market Reaches New High
by Christopher Vargas
The stock market closed at a record high today as the DJIA rose over 42 points and the S&P 500 gained 0.4%.
Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug
by Zacks Equity Research
Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.
Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex
by Zacks Equity Research
Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
by Zacks Equity Research
Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.
The Zacks Analyst Blog Highlights: Booking, Allergan, Honda Motor, Infosys and Activision Blizzard
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Booking, Allergan, Honda Motor, Infosys and Activision Blizzard
Top Stock Reports for Booking Holdings, Allergan & Honda Motor Co.
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Booking Holdings (BKNG), Allergan (AGN) and Honda Motor (HMC).
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
Teva (TEVA) Q3 Earnings Miss, Stock Up on Guidance Increase
by Zacks Equity Research
Teva Pharmaceutical (TEVA) misses earnings estimate but beats the same for sales. The company increases the lower end of its 2019 sales and earnings guidance. Shares rise.
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
by Kinjel Shah
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed
by Zacks Equity Research
Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View
by Zacks Equity Research
Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Allergan (AGN) Q3 Earnings Meet Estimates
by Zacks Equity Research
Allergan (AGN) delivered earnings and revenue surprises of 0.00% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, which are supposed to release their quarterly results on Nov 5.
Should You Buy Allergan (AGN) Ahead of Earnings?
by Zacks Equity Research
Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Allergan (AGN) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Allergan (AGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View
by Zacks Equity Research
AbbVie (ABBV) beats on both earnings and revenues in the third quarter. The company ups the lower end of its 2019 guidance for adjusted earnings per share.